Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
5.50
-0.03 (-0.54%)
Jun 9, 2026, 4:00 PM EDT - Market closed

Plus Therapeutics Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Plus Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $36. The average 1-year stock price forecast is 554.55% higher than the current stock price, while the lowest is $12 (+118.18%) and the highest is $57 (+936.36%).

Price Target: $36 (+554.55%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$12$36$37.5$57
Change+118.18%+554.55%+581.82%+936.36%

Analyst Ratings

The average analyst rating for Plus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy343333
Buy111111
Hold001100
Sell000000
Strong Sell000000
Total455544

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Maxim Group
Maxim Group
Buy
Maintains
$12
BuyMaintains$12+118.18%May 20, 2026
Lake Street
Lake Street
Buy
Maintains
$50
BuyMaintains$50+809.09%May 19, 2026
Ascendiant
Ascendiant
Buy
Maintains
$65
BuyMaintains$65+1,081.82%Apr 8, 2026
D. Boral Capital
D. Boral Capital
Hold
Downgrades
n/a
HoldDowngradesn/an/aMar 31, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$25
BuyReiterates$25+354.55%Mar 16, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
6.30M
from 5.21M
Increased by 20.76%
Revenue Next Year
19.14M
from 6.30M
Increased by 204.05%
EPS This Year
-3.92
from -0.29
EPS Next Year
-2.40
from -3.92
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-224.00K4.91M5.82M5.21M6.30M
Revenue Growth
--2,093.30%18.54%-10.49%20.76%
Gross Profit
-5.32M-9.47M-4.78M-4.76M-3.17M3.78M
Gross Margin
--4,229.46%-97.23%-81.66%-60.73%60.00%
Operating Income
-12.18M-19.71M-13.32M-14.70M-15.30M-27.27M
Net Income
-13.40M-20.28M-13.32M-12.98M-22.39M-26.80M
EPS
-----0.29-3.92
Free Cash Flow
-5.18M-8.21M-8.43M-3.35M-13.60M-21.58M
No. Analysts
-----4
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High10.5M
Avg6.3M
Low4.0M

Revenue Growth

Revenue Growth202620272028
High
102.0%
Avg
20.8%
Low
-23.3%

EPS Forecast

EPS202620272028
High-3.39
Avg-3.92
Low-4.78

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-